Elite in Myasthenia Gravis

Dr. Mazen Dimachkie

Neurology
Office
3599 Rainbow Blvd # Stp, 
Kansas City, KS 
Offers Telehealth
Elite in Myasthenia Gravis
Office
3599 Rainbow Blvd # Stp, 
Kansas City, KS 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Dr. Mazen Dimachkie, MD is a Clinical Neurophysiologist in Kansas City, KS and has over 34 years of experience in the medical field. He graduated from American University of Beirut / Faculty of Medicine in 1988. He is affiliated with medical facilities LMH Health and University Of Kansas Hospital.

Dr. Dimachkie is rated as an Elite provider by MediFind in the treatment of Myasthenia Gravis. His top areas of expertise are Myositis, Inclusion Body Myositis, Myasthenia Gravis, Thymectomy, and Tissue Biopsy.

His clinical research consists of co-authoring 198 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 27 articles and participated in 1 clinical trial in the study of Myasthenia Gravis.

Residency
University of Texas Health Science Center
Specialties
Neurology
Licenses
Psychiatry & Neurology in KS
Board Certifications
American Board Of Psychiatry And Neurology Neurology
American Board Of Psychiatry And Neurology Clinical Neurophysiology
American Board Of Psychiatry And Neurology Neuromuscular Medicine
Hospital Affiliations
LMH Health
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Home State Health
  • EPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Sunflower Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

Office
3599 Rainbow Blvd # Stp, Kansas City, KS 66103
Other Locations
University of Kansas Hospital Transplant Center
3901 Rainbow Blvd, Kansas City,, KS 66160

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

Inclusion Body Myositis Treatment With Celution Processed Adipose Derived Regenerative Cells
Inclusion Body Myositis Treatment With Celution Processed Adipose Derived Regenerative Cells
Enrollment Status: Completed
Publish Date: December 17, 2025
Intervention Type: Device
Study Phase: Not Applicable
A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of VM202 in Participants With Painful Diabetic Peripheral Neuropathy
A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of VM202 in Participants With Painful Diabetic Peripheral Neuropathy
Enrollment Status: Completed
Publish Date: October 09, 2025
Intervention Type: Other, Biological
Study Phase: Phase 3
Long-term, Prospective, Non-interventional, Extension of a Phase III, Randomized, Placebo-controlled, Multicenter Study to Assess the Safety & Efficacy of Engensis (VM202) in Subjects With Painful Diabetic Peripheral Neuropathy
Long-term, Prospective, Non-interventional, Extension of a Phase III, Randomized, Placebo-controlled, Multicenter Study to Assess the Safety & Efficacy of Engensis (VM202) in Subjects With Painful Diabetic Peripheral Neuropathy
Enrollment Status: Completed
Publish Date: October 09, 2025
Intervention Type: Drug, Genetic
Study Phase: Phase 3
A Phase 2b/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 12 Month Clinical Trial to Evaluate the Efficacy and Safety of MN-166 (Ibudilast) Followed by Open-Label Extension Phase in Subjects With Amyotrophic Lateral Sclerosis
A Phase 2b/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 12 Month Clinical Trial to Evaluate the Efficacy and Safety of MN-166 (Ibudilast) Followed by Open-Label Extension Phase in Subjects With Amyotrophic Lateral Sclerosis
Enrollment Status: Active_not_recruiting
Publish Date: September 16, 2025
Intervention Type: Drug
Study Drug: MN-166
Study Phase: Phase 2/Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy of ManNAc in Subjects With GNE Myopathy
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy of ManNAc in Subjects With GNE Myopathy
Enrollment Status: Active_not_recruiting
Publish Date: June 13, 2025
Intervention Type: Other, Drug
Study Drug: N-Acetylmannosamine
Study Phase: Phase 2
International GBS Outcome Study (IGOS): a Prospective INC Study on Clinical and Biological Predictors of Disease Course and Outcome in Guillain-Barré Syndrome (GBS).
International GBS Outcome Study (IGOS): a Prospective INC Study on Clinical and Biological Predictors of Disease Course and Outcome in Guillain-Barré Syndrome (GBS).
Enrollment Status: Completed
Publish Date: December 12, 2024
Influence of NT5c1A Antibodies on Disease Progression, Clinical Phenotype and Blood and Muscle Biomarkers in Sporadic Inclusion Body Myositis - A Prospective Evaluation (INSPIRE-IBM Study)
Influence of NT5c1A Antibodies on Disease Progression, Clinical Phenotype and Blood and Muscle Biomarkers in Sporadic Inclusion Body Myositis - A Prospective Evaluation (INSPIRE-IBM Study)
Enrollment Status: Active_not_recruiting
Publish Date: April 09, 2024
Phase II Study of Arimoclomol for the Treatment of Sporadic Inclusion Body Myositis (IBM)
Phase II Study of Arimoclomol for the Treatment of Sporadic Inclusion Body Myositis (IBM)
Enrollment Status: Completed
Publish Date: May 10, 2023
Intervention Type: Other, Drug
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis
Enrollment Status: Completed
Publish Date: August 16, 2022
Intervention Type: Drug
Study Drug: Lenabasum
Study Phase: Phase 3
Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis
Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis
Enrollment Status: Completed
Publish Date: October 30, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of lGIV-C as a Corticosteroid Sparing Agent in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of lGIV-C as a Corticosteroid Sparing Agent in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis
Enrollment Status: Completed
Publish Date: March 30, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients With Dermatomyositis
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients With Dermatomyositis
Enrollment Status: Completed
Publish Date: October 10, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 11 Less Clinical Trials

186 Total Publications

Reply to the Letter to the Editor: The Role of Patient-Reported Symptoms in Standardizing MGFA Class 0 and MGFA-PIS.
Reply to the Letter to the Editor: The Role of Patient-Reported Symptoms in Standardizing MGFA Class 0 and MGFA-PIS.
Journal: Muscle & nerve
Published: August 26, 2025
Similar Doctors
Elite in Myasthenia Gravis
Dr. Mamatha Pasnoor
Neurology
Elite in Myasthenia Gravis
Dr. Mamatha Pasnoor
Neurology

Office

3599 Rainbow Blvd, 
Kansas City, KS 
 (0.4 miles away)
913-574-0834
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mamatha Pasnoor is a Neurologist in Kansas City, Kansas. Dr. Pasnoor is rated as an Elite provider by MediFind in the treatment of Myasthenia Gravis. Her top areas of expertise are Myasthenia Gravis, Chronic Inflammatory Demyelinating Polyneuropathy, Peripheral Neuropathy, Thymectomy, and Tissue Biopsy.

Richard Barohn
Elite in Myasthenia Gravis
Dr. Richard Barohn
Neurology
Elite in Myasthenia Gravis
Dr. Richard Barohn
Neurology

Office

3599 Rainbow Blvd, 
Kansas City, KS 
 (0.4 miles away)
913-588-6985
Languages Spoken:
English
See accepted insurances

Richard Barohn is a Neurologist in Kansas City, Kansas. Dr. Barohn is rated as an Elite provider by MediFind in the treatment of Myasthenia Gravis. His top areas of expertise are Inclusion Body Myositis, Myositis, Myasthenia Gravis, Thymectomy, and Tissue Biopsy.

Distinguished in Myasthenia Gravis
Dr. Constantine Farmakidis
Neurology
Distinguished in Myasthenia Gravis
Dr. Constantine Farmakidis
Neurology

Kansas University Physicians Inc

3901 Rainbow Blvd, 
Kansas City, KS 
 (0.2 miles away)
913-588-7775
Languages Spoken:
English, French, Greek, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Constantine Farmakidis is a Neurologist in Kansas City, Kansas. Dr. Farmakidis is rated as a Distinguished provider by MediFind in the treatment of Myasthenia Gravis. His top areas of expertise are Myasthenia Gravis, Paramyotonia Congenita, Charcot-Marie-Tooth Disease, Tomaculous Neuropathy, and Thymectomy. Dr. Farmakidis is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Dimachkie's expertise for a condition
ConditionClose
View All 7 Elite Conditions
View All 9 Distinguished Conditions
View All 23 Advanced Conditions
View All 49 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile